Loading...
Avenue Therapeutics, Inc.
ATXI•NASDAQ
Healthcare
Biotechnology
$0.51
$-0.14(-21.54%)
Avenue Therapeutics, Inc. (ATXI) Financial Performance & Income Statement Overview
Review Avenue Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
22.40%
↑ 22.40%
Net Income Growth
-12.29%
↓ 12.29%
Operating Cash Flow Growth
4.50%
↑ 4.50%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-399.33%
↓ 399.33%
ROIC
-406.52%
↓ 406.52%
Avenue Therapeutics, Inc. (ATXI) Income Statement & Financial Overview
Review Avenue Therapeutics, Inc.'s (ATXI) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $565000.00 | $2.33M | $1.36M | $2.39M |
| SG&A Expenses | $1.03M | $829000.00 | $1.46M | $1.32M |
| Operating Expenses | $1.60M | $3.16M | $2.82M | $3.71M |
| Total Costs & Expenses | $1.60M | $3.16M | $2.82M | $3.71M |
| Interest Income | $24000.00 | $51000.00 | $52000.00 | $49000.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $69000.00 | $122000.00 | $3.71M |
| EBITDA | -$1.56M | -$3.09M | -$2.70M | $0.00 |
| EBITDA Ratio | ||||
| Operating Income | -$1.60M | -$3.16M | -$2.82M | -$3.71M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $37000.00 | $69000.00 | $122000.00 | -$641000.00 |
| Income Before Tax | -$1.56M | -$3.09M | -$2.70M | -$4.35M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $9000.00 |
| Net Income | -$1.54M | -$3.08M | -$7.19M | -$4.34M |
| Net Income Ratio | ||||
| EPS | $0.00 | -$1.92 | -$6.43 | -$7.72 |
| Diluted EPS | $0.00 | -$1.92 | -$6.43 | -$7.72 |
| Weighted Avg Shares Outstanding | $1.60M | $1.60M | $1.12M | $562045.00 |
| Weighted Avg Shares Outstanding (Diluted) | $1.60M | $1.60M | $1.12M | $562045.00 |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan